Novo Nordisk(NVO)
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in nine countries, and affiliates or offices in five countries. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 25% of its shares and a supermajority (45%) of its voting shares.
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
Mock data
Subscribe for the real data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name | Drug Name | Approved | Patent Expires | Indication |
|---|---|---|---|---|
| Actraphane | Insulin human | 2002-10-07 | ||
| Actrapid | Insulin human | 2002-10-07 | ||
| Esperoct | Antihemophilic factor, Turoctocog alfa | 2019-02-19 | — | |
| Fiasp | Insulin aspart | 2017-09-29 | ||
| Glucagen | Glucagon | 1998-06-22 | 2036-2039 | |
| Innofem | Estradiol | 1999-11-19 | 2024-2037 | |
| Insulatard | Insulin human | 2002-10-07 | ||
| Levemir | Insulin detemir | 2005-06-16 | ||
| Mixtard | Insulin human | 2002-10-07 | ||
| Monotard | Insulin human | 2002-10-07 | ||
| Norditropin | Somatropin | 2000-06-20 | ||
| Novoeight | Antihemophilic factor human recombinant | 2013-10-15 |
1
2
3
4
>
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Indication |
|---|---|---|---|---|---|
1
2
3
4
5
6
...
8
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use